MedTrace Logo

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

NCT02381808 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2017-06-07

No results posted yet for this study

Summary

To understand 295 gene mutation mutation status (include EGFR, HER2, KRAS, BRAF, PIK3CA,ect) by deep sequencing in Chinese patients with pulmonary adenocarcinoma and their relationships with the patients' clinical features (including sex, age, smoking history and adenocarcinoma subtype), specify the predictive significance of the genes mutations for new targeted therapies in NSCLC patients, and better understand the molecular mechanism drug resistance to EGFR-TKIs.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

Principal Investigators

  • China China · Guang general hospital,Guangzhou, Guangdong, China, 510080

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-06-24
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02381808 on ClinicalTrials.gov